Which medication is NOT classified as a PSCK-9 inhibitor?

The medication that is classified as NOT a PCSK9 inhibitor is Aspirin. PCSK9 inhibitors are a specific class of medications aimed at lowering cholesterol levels by inhibiting the protein PCSK9, which leads to increased clearance of LDL cholesterol from the bloodstream. Alirocumab and Evolocumab are both well-known examples of PCSK9 inhibitors, designed to effectively lower LDL cholesterol levels in patients at risk for cardiovascular diseases. Repatha is the brand name for Evolocumab, further solidifying its classification as a PCSK9 inhibitor.

Aspirin, however, does not belong to this category. It is primarily an antiplatelet medication that works by inhibiting platelet aggregation, thus reducing the risk of blood clots. While Aspirin can play a role in cardiovascular disease prevention by decreasing the risk of clot formation, it does not have the direct effects on cholesterol metabolism that PCSK9 inhibitors do. Therefore, Aspirin is the correct answer as it does not classify as a PCSK9 inhibitor.